Search

Corvus Pharmaceuticals Inc

Atidarymo kaina

13.24 2.08

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.88

Max

13.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+142.33% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-261M

1.1B

Ankstesnė atidarymo kaina

11.16

Ankstesnė uždarymo kaina

13.24

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-29 23:56; UTC

LifeVantage Corp shares are trading lower in after-market hours. No specific news was identified to explain this movement.

2026-07-29 23:56; UTC

Zoom Video Communications Inc is trading lower in after-market hours. Broader market uncertainty regarding future interest rate decisions may be influencing investor sentiment.

2026-07-29 23:56; UTC

Harrow Inc shares are lower in after-market hours amid broad weakness in the Pharmaceuticals sub-sector, with the price significantly below its 20-day moving average.

2026-07-29 23:56; UTC

Sprinklr Inc. shares are higher in after-market trading, continuing an upward trajectory amid positive market sentiment following the Federal Reserve's expected interest rate decision.

2026-07-29 23:56; UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

2026-07-29 23:56; UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

2026-07-29 23:56; UTC

Archer-Daniels-Midland shares are higher in after-hours trading, reflecting stability despite no specific news to explain the movement.

2026-07-29 23:56; UTC

Correlated Moves

Corsair Gaming Inc shares are higher in after-market trading, supported by positive sentiment and strength in small-cap stocks, including the Russell 2000 Index.

2026-07-29 23:56; UTC

Standard BioTools Inc. shares traded roughly flat during after-market hours, showing little change since Wednesday's close amid a stable trading range.

2026-07-29 23:56; UTC

Axon Enterprise Inc. shares advanced slightly in after-market trading, reflecting routine performance, though they remain below their 20-day moving average.

2026-07-29 23:56; UTC

Correlated Moves

Pentair PLC shares are higher in after-market trading, reflecting a positive trend in the Russell 2000 Index and steady interest rates from the Federal Reserve.

2026-07-29 23:56; UTC

Correlated Moves

Cloudflare Inc. trades higher in after-market hours, reflecting strength near its one-month range. The move aligns with trends in the cybersecurity sector.

2026-07-29 23:56; UTC

Clorox Co. shares declined in after-market trading, despite recovering from earlier lows. The stock remains above its 20-day moving average.

2026-07-29 23:56; UTC

Correlated Moves

Okta Inc shares rose in after-market trading, reflecting positive momentum in the cybersecurity sector and broader market sentiment regarding steady interest rates.

2026-07-29 23:56; UTC

Correlated Moves

DR Horton shares are higher in after-market trading, supported by a rising Russell 2000 Index and stable interest rate expectations from the Federal Reserve.

2026-07-29 23:56; UTC

Trade Desk Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average after four consecutive higher daily closes.

2026-07-29 23:56; UTC

Powell Industries shares are higher in after-market trading, despite a generally flat cumulative return and ongoing uncertainty regarding interest rates.

2026-07-29 23:56; UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

2026-07-29 23:56; UTC

Correlated Moves

Energy Fuels Inc shares are higher in after-market hours, reflecting a correlation with Cameco Corp's recent gains amid broader market uncertainty over interest rates.

2026-07-29 23:56; UTC

AeroVironment Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close amid cautious market sentiment regarding interest rate expectations.

2026-07-29 23:56; UTC

Campbell Soup Co. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

2026-07-29 23:56; UTC

Correlated Moves
ETF Constituents
Macro News

Financial Select Sector SPDR Fund trades higher in after-market hours, supported by gains from key holdings and a rise in the Dow Jones Index.

2026-07-29 23:56; UTC

Alcoa Corp shares advanced modestly in after-market trading following Wednesday's close, amid uncertainty over future interest rate changes.

2026-07-29 23:56; UTC

Correlated Moves

Lennar Corp sees a modest increase in after-market trading, supported by positive market sentiment and a rise in the Russell 2000 Index.

2026-07-29 23:56; UTC

Alphabet Inc. shares declined in after-market trading, reflecting a cumulative drop since Wednesday's close and remaining below the 20-day moving average.

2026-07-29 23:56; UTC

Social Media

Alphabet Inc shares declined in after-market trading, remaining below their 20-day moving average amid ongoing market uncertainty about future rate hikes.

2026-07-29 23:56; UTC

Macro Event

Cardano is higher today amid expectations of a future Fed rate hike, despite ongoing geopolitical tensions and easing inflation data.

2026-07-29 23:56; UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

2026-07-29 23:56; UTC

Macro News
ETF Constituents

Utilities Select Sector SPDR Fund trades higher in after-market hours, buoyed by strong returns from NextEra Energy and Entergy amid rising geopolitical tensions.

2026-07-29 23:56; UTC

Viridian Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. Broader market uncertainty persists.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

142.33% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  142.33%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat